Showing results (1521-1530 of 3,100) with videos related to
Sort By:
Pageof 310
Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.Expert Review of Anticancer Therapy|June 13, 2022
Medullary thyroid carcinoma: a narrative historical reviewAmanda Wong, Kylie Nabata, Sam M WisemanExpert Review of Anticancer Therapy|June 14, 2022
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approvalHollis Viray, David F McDermott, David J EinsteinExpert Review of Anticancer Therapy|June 21, 2022
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areasLorenzo Belluomini, Alice Avancini, Luca Pasqualin, et al.Expert Review of Anticancer Therapy|June 29, 2022
Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignanciesDinakshi Shah, Zainul Abedin Kapacee, Angela Lamarca, et al.Expert Review of Anticancer Therapy|May 21, 2019
The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysisQin Qin, Bing Peng, Baosheng LiExpert Review of Anticancer Therapy|May 28, 2019
Risk stratification of upper tract urothelial carcinoma: A Review of the Current LiteratureMehdi Kardoust Parizi, Petr V Glybochko, Dmitry Enikeev, et al.Expert Review of Anticancer Therapy|April 7, 2022
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimensKai Cc Johnson, Dionisia Quiroga, Preeti Sudheendra, et al.Expert Review of Anticancer Therapy|April 7, 2022
Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approachTimothy J Voorhees, Narendranath EpperlaExpert Review of Anticancer Therapy|July 22, 2010
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsCliona Grant, Fahd Rahman, Richard Piekarz, et al.Pageof 310